Get Permission Ambresh and Shilpa A: Assessment of plasma fibrinogen as a marker of diabetic nephropathy


Introduction

Diabetes is one of the most common chronic hyperglycemic syndrome. Diabetic Nephropathy is one of the major complications of DM characterized by persistent albuminuria, increased arterial blood pressure, a relentless decline in glomerular filtration rate (GFR) & a high risk of cardiovascular morbidity & mortality.1

The biological marker of DN is fibrinogen. Fibrinogen, is increased in diabetic patients.2, 3 An increase in plasma fibrinogen levels is also considered an independent risk factor for diabetic nephropathy.4 Fibrinogen is the major coagulation protein in blood. It is a glycoprotein and circulates as a dimer composed of three pairs of polypeptide chains.5 It is an acute phase protein & increases during the inflammatory process. Inflammation plays an important role in the development of atherosclerosis. Monocytes infiltrating the atherosclerosis differentiate into macrophages that release cytokines, such as interleukin-6, which increase plasma fibrinogen levels in serum.

Diabetes mellitus leads to dyslipidemia and this dyslipidemia is more in presence of DN.

Lipid ratios are better indicators of atherogenic risk in patients with DN as compared to lipidsalone.6 Creatinine is not raised above the normal range until 60% of total kidney function is lost. Hence, the more accurate means of measuring renal function is eGFR. Microalbuminuria in DN is best investigated by the urinary albumin excretion in relation to creatinine, as assessed from the albumin-to-creatinine ratio.7

Hence, the present study was undertaken to estimate plasma fibrinogen levels in DM & DN and to know whether these levels could be used as early predictors of DN.

Objectives

To find out whether the levels of Plasma Fibrinogen levels can be used as markers for the early diagnosis of DN.

Materials and methods

Study design

Case control study

The study includes total of 150 patients, of which 50 were diabetic without any complications, 50 were diabetic nephropathy patients and remaining 50 were age matched healthy controls.

Study period & duration

The study was conducted from 1st January 2015 to 31st December 2015

Study site

Study was conducted in Department of Biochemistry of a tertiary care hospital.

Patients were recruited from out-patient department (OPD) and inpatient department (IPD) of medicine and nephrology of tertiary care hospital.

Ethical committee approval

The permission of Institutional Ethics Committee (IEC) was taken before starting the study.

Ethical Committee Approval No-VIMS/PG/IEC/14/2014-15 dated 07.11.2014

Informed consent

All the patients enrolled in the study were explained about the purpose of the study in their own language and a written informed consent was taken as given in annexure II.

Selection criteria

Inclusion criteria

Patients of both gender aged above 30 years, diagnosed as type 2 diabetes mellitus by clinicians according to American Diabetes Association (ADA) guidelines and

Patients diagnosed as diabetic nephropathy by clinicians.

Exclusion criteria

  1. Type 1 diabetes mellitus

  2. Patients with severe complications of diabetes mellitus other than nephropathy

  3. Pregnant women

  4. Patients with history of – acute febrile illness, current episode of urinary tract infection, pyelonephritis, urinary tract obstruction, congestive heart failure or acute coronary syndrome

  5. Patients with gout & patients on anti-inflammatory drug or allopurinol

  6. History of kidney transplant

  7. Albuminuria documented due to causes that are other than diabetes

Methodology

Patients attending medicine and nephrology departments were examined.

Patients satisfying inclusion & exclusion criteria were included in the study

Results

The study includes total of 150 patients, studied in 3 groups. Group I- 50, age & sex matched healthy controls; group II- 50, diabetic patients without any complications and group III- 50, diabetic nephropathy patients.

The mean age of subjects in 3 groups - control, DM & DN were 40.5± 10.9 years, 51.46± 11.3 years & 51.9 ± 8.38 years respectively as shown in Table 1.

Table 1

Mean Age in Study groups

Particulars

Control

DM

DN

Age (in yrs.)

40.5 ± 10.9

51.46 ± 11.3

51.9 ± 8.38

The age group of all study subjects ranged from 25 to 70 years & majority of study subjects were in the age groups of 41-50 years as shown below in Table 2.

Table 2

Age Distribution in Study groups

Age (yrs.)

Control

DM

DN

Percentage

25-30

11

2

-

2%

31-40

15

11

5

12%

41-50

17

18

17

34%

51-60

6

8

18

30%

61-70

1

11

10

22%

Total

50

50

50

100%

Table 3

Mean Duration of diabetes in study groups

DM

DN

P value

Duration of Diabetes (years)

3.58 ± 3.13

10.14 ± 3.07

0.0001

Based on the duration of diabetes, the subjects in DM group were divided as shown in Table 4.

Table 4

Distribution based on Duration of diabetes in DM group

Duration of DM (years)

No of patients in DM group

< 1

3

1-2

9

2-3

13

3-4

10

4-5

8

5-10

4

10-15

3

Total

50

The subjects in DN group were studied according to the duration of diabetes as shown in Table 5. Many of the study subjects included in this group were of 10-13years of diabetes.

Table 5

Distribution based on Duration of diabetes in DN group

Duration of DM (years)

DN group

< 5

1

5-8

8

8-10

11

10-13

17

13-15

13

Total

50

The study subjects of 2 groups (DM & DN) were compared based on duration of diabetes, which is shown below; as the duration of diabetes increases the incidence of nephropathy also increased as shown in the Table 6.

Table 6

Comparison of Distribution of Duration of diabetes between 2 groups

Duration of DM (yrs.)

DM group

DN group

1-3

25

-

3-5

18

1

5-8

2

8

8-10

2

11

10-13

3

17

13-15

-

13

Total

50

50

The study subjects in DN group was distributed based on the duration of nephropathy as shown in Table 7 which showed majority of patients included in the study were suffering from nephropathy since 1-2 years.

Table 7

Distribution of DN patients based on duration of nephropathy

Duration of nephropathy (years)

No of patients

<1

6

1-2

22

2-3

15

3-4

4

4-5

1

5-6

2

The mean plasma fibrinogen level in control group was 190.34 ± 72.83mg/dl. The mean plasma fibrinogen levels in DM & DN groups were 522.76 ± 115.79 mg/dl & 657.64 ± 124.61 mg/dl respectively as shown in Table 8. There was statistically significant increase of fibrinogen levels in DM & DN groups with a p value of 0.0001.

Table 8

Plasma Fibrinogen levels in study groups

Controls

DM

DN

P. Fibrinogen (mg/dl)

190.34 ± 72.83

522.76± 115.79*

657.64 ± 124.61*†

Figure 1

Plasma Fibrinogen levels in study groups

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ffe451ad-37cf-429d-a292-d286350b6207image1.png

FBS was studied in all 3 groups. The mean FBS levels in control, DM & DN groups were 71.94 ± 15.6 mg/dl, 123.38 ± 44.36mg/dl & 178.3 ± 66.57mg/dl respectively as shown in the Table 9. FBS levels were increased in DM group & DN group when compared to control group which was statistically significant with a p value of 0.0001. The increased FBS levels in DN group when compared to DM group was also statistically very significant.

Table 9

FBS levels in study groups

Controls

DM

DN

FBS (mg/dl)

71.94 ± 15.6

123.38 ± 44.36*

178.3 ± 66.57*†

The mean HbA1c level in control group was 5.95 ± 0.29 %. The mean HbA1c levels in DM & DN groups were 7.60 ± 0.51%& 7.83 ± 0.48% respectively. HbA1c level was increased in DM & DN groups when compared to controls with a p value of 0.0001. There was only a slight increase of HbA1c levels in DN group when compared to DM group as shown in Table 10. P value between groups was statistically significant.

Table 10

HbA1c levels in study groups

Controls

DM

DN

HbA1c (%)

5.95 ± 0.29

7.60 ± 0.51*

7.83 ± 0.48*†

The mean Blood Urea level in control group was 21.48 ± 4.89 mg/dl. The mean B Urea levels in DM & DN groups were 34.04 ± 10.91 mg/dl & 75.86 ± 31.24 mg/dl respectively as shown in Table 14 . The mean Serum Creatinine levels of control, DM & DN groups were 0.82 ± 0.22mg/dl, 1.20 ± 0.21mg/dl & 5.39 ± 2.42mg/dl respectively as shown in the table no 11. Blood Urea & Serum Creatinine levels were increased in DM group & DN group when compared to control group with further increase in DN group.

Table 11

Blood Urea & Serum Creatinine levels in study groups

Controls

DM

DN

B Urea (mg/dl)

21.48 ± 4.89

34.04 ± 10.91*

75.86 ± 31.24*†

S Creatinine (mg/dl)

0.82 ± 0.22

1.20 ± 0.21*

5.39 ± 2.42*†

Table 12

Mean, standard deviation (SD) of all the parameters

S. No

Assay parameters

Controls

DM

DN

Mean

SD

Mean

SD

Mean

SD

1.

Plasma Fibrinogen

190.34

72.83

522.76

115.79

657.05

131.50

2.

FBS

71.94

15.66

123.38

44.36

174.75

65.83

3.

HbA1c

5.954

0.29

7.606

0.512

7.86

0.49

4.

TC

101

20.13

192.46

49.57

231.525

53.19

5.

Triglyceride

121.78

17.16

194.64

25.95

249.38

86.92

6.

LDL

56.36

28.41

110.86

28.21

128.275

34.03

7.

HDL

30.2

4.90

24.48

3.97

19.675

2.99

8.

Blood Urea

21.48

4.89

34.04

10.917

77

32.03

10.

Serum Creatinine

0.82

0.22

1.204

0.210

5.63

2.53

11.

TC/HDL

3.41

0.85

8.03

2.404

12.01

3.18

12.

LDL/HDL

1.94

1.106

4.63

1.421

5.28

1.35

13.

eGFR

111.36

38.81

62.20

14.83

13.52

7.26

14.

Urine A/C ratio

0.072

0.060

0.12

0.072

0.42

0.16

Table 13

P values of all parameters between groups

Control & DM

C & DN

DM & DN

Sialic acid

0.0001

0.0001

0.0463

Firbinogen

0.0001

0.0001

0.0001

FBS

0.0001

0.0001

0.0001

HbA1c

0.0001

0.0001

0.0179

TC

0.0001

0.0001

0.0005

Triglyceride

0.0001

0.001

0.0004

LDL

0.0001

0.0001

0.0094

HDL

0.0001

0.0001

0.0001

B Urea

0.0001

0.0001

0.0001

S Creat

0.0001

0.0001

0.0001

TC/HDL

0.0001

0.0001

0.0001

LDL/HDL

0.0001

0.0001

0.0293

eGFR

0.0001

0.0001

0.0001

U A/C ratio

0.0004

0.0001

0.0001

SA & fibrinogen levels were correlated with levels of FBS, HBA1C, LDL, HDL, TC, Blood Urea, serum creatinine, TC/HDL, LDL/HDL, eGFR& Urine A/C ratio in DM &DN group as shown in Table 14.

Table 14

Correlation coefficients of fibrinogen levels with other risk factors in DM & DN

Risk factors

Correlation coefficient (r) of Fibrinogen

DM

DN

FBS

0.2

0.2

HbA1C

0.41

0.5

TC

0.1

0.3

Triglyceride

0.40

0.5

LDL

0.1

0.24

HDL

-0.1

-0.23

B Urea

0.04

0.31

S Creatinine

0.11

0.35

TC/HDL

0.11

0.21

LDL/HDL

0.3

0.5

eGFR

-0.25

-0.2

Urine A/C ratio

0.33

0.48

Figure 2

Correlation between Fibrinogen & TC in Diabetic Nephropathy patients

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ffe451ad-37cf-429d-a292-d286350b6207image2.png

Figure 3

Correlation between fibrinogen &triglyceride in diabetic nephropathy patients

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ffe451ad-37cf-429d-a292-d286350b6207image3.png

Figure 4

Correlation between Fibrinogen & LDL in Diabetic Nephropathy patients

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ffe451ad-37cf-429d-a292-d286350b6207image4.png

Figure 5

Correlation between Fibrinogen & HDL in Diabetic Nephropathy patients

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ffe451ad-37cf-429d-a292-d286350b6207image5.png

Blood Urea & serum creatinine had positive correlation coefficients of 0.04 & 0.11 in DM group and 0.31 (p value = 0.02) & 0.35 (p value = 0.01) in DN group respectively.Thus both parameters had linear correlation in DN group with fibrinogen as shown in Figure 6 .

Figure 6

Correlation between Fibrinogen & Blood Urea in Diabetic Nephropathy patients

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ffe451ad-37cf-429d-a292-d286350b6207image6.png

Figure 7

Correlation between Fibrinogen & S Creatinine in Diabetic Nephropathy patients

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ffe451ad-37cf-429d-a292-d286350b6207image7.png

Atherogenic ratios- TC/HDL & LDL/HDL when correlated with fibrinogen had positive correlation with r values of 0.11 & 0.3 in DM group & 0.21 (p value = 0.05) & 0.5 (p value = 0.0002) in DN group respectively as shown in Figure 8.

Figure 8

Correlation between Fibrinogen & TC/HDL in Diabetic Nephropathy patients

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ffe451ad-37cf-429d-a292-d286350b6207image8.png

Figure 9

Correlation between Fibrinogen & LDL/HDL in Diabetic Nephropathy patients

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ffe451ad-37cf-429d-a292-d286350b6207image9.png

Correlation coefficient between fibrinogen & eGFR was -0.25 & -0.2 (p value =0.05) in DM & DN groups respectively as shown in Figure 10. Thus eGFR was negatively correlated with fibrinogen.

Figure 10

Correlation between Fibrinogen & eGFR in Diabetic Nephropathy patients

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ffe451ad-37cf-429d-a292-d286350b6207image10.png

Urine A/C ratio had positive correlation with fibrinogen with r value of 0.33 & 0.48 (p value =0.0004) in DM & DN groups respectively as shown in Figure 11.

Figure 11

Correlation between Fibrinogen & Urine A/C ratio in Diabetic Nephropathy patients

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/ffe451ad-37cf-429d-a292-d286350b6207image11.png

The mean plasma fibrinogen level in control group was 190.34 ± 72.83mg/dl. The mean plasma fibrinogen levels in DM & DN groups were 522.76 ± 115.79 mg/dl & 657.64 ± 124.61 mg/dl respectively. In our study, fibrinogen levels were increased significantly in DM group compared to controls which was further increased in DN group which is in accordance to study done by Venkataramana G et al,8 Laurell et al,9 Alper et al.10 Hence above studies interpret that fibrinogen increases in diabetes with complications. Our findings were also similar to studies done by Killingsworth et al, Ganda et al, Collier et al, Schmidtz et al & Eraslan M et al.11, 12, 13, 14 The cause of increased fibrinogen production in type 2 DM are insulin resistance, hyperglucagonemia acting as stimulators of fibrinogen production in the liver, and possibly, also a subclinical inflammatory state. Thus diabetic patients should be followed up with fibrinogen levels to prevent complications like diabetic nephropathy.

The mean FBS levels of control, DM & DN groups were 71.94 ± 15.6 mg/dl, 123.38 ± 44.36mg/dl & 178.3 ± 66.57mg/dl respectively. FBS levels were increased in DM group & DN group when compared to control group which was statistically significant.

The mean HbA1c level in control group was 5.95 ± 0.29 %. The mean HBA1c levels in DM & DN groups were 7.60 ± 0.51% & 7.83 ± 0.48% respectively. HBA1c level was increased in DM & DN groups when compared to controls with a (p= 0.0001) which was statistically significant. There was only a slight increase of HBA1c levels in DN group when compared to DM group.

We also observed that plasma fibrinogen concentrations were significantly increased and positively co-related with several known risk factors, notably FBS, glycemic control (HbA1c), lipid profile, Blood urea, Serum creatinine& UAC whereas negatively correlated with HDL & eGFR in DM & DN groups. At present microalbuminria is considered as the earliest marker for DN. In our study fibrinogen correlated positively with UAC. These findings strengthen the hypothesis that an increase in circulating inflammatory biomarkers like fibrinogen levels are early manifestation of diabetic renal disease. Hence, plasma fibrinogen levels could be used for early diagnosis of DN. The results of our study are completely in accordance with recent studies with the same concept.15

Conclusion

Fibrinogen correlated positively with FBS, HbA1c, TC, triglyceride, LDL, Blood Urea, serum creatinine, TC/HDL, LDL/HDL & urine A/C ratio in both DM & DN group, whereas there was negative correlation of fibrinogen with HDL & eGFR. Thus fibrinogen could be used as early biomarkers for the diagnosis of DN.

Summary

The present study consists of total 150 patients, studied in 3 groups, group I- 50 were age & sex matched healthy controls, group II- 50 were diabetic patients and group III- 50 were diabetic nephropathy patients. The aim of the study was to fibrinogenin type 2 DM, DN patients and healthy controls, to correlate fibrinogen levels with FBS, HBA1c, Lipid profile, Blood Urea, Serum Creatinine, eGFR and urine A/C ratio in type 2 DM and DN patients and to find out whether fibrinogen can be used as markers for the early diagnosis of DN. The mean plasma fibrinogen level in control group was 190.34 ± 72.83mg/dl. The mean plasma fibrinogen levels in DM & DN groups were 522.76 ± 115.79 mg/dl & 657.64 ± 124.61 mg/dl respectively. There was progressive statistically significant increase of fibrinogen levels in DM & DN groups with a p value of 0.0001.Correlation coefficient between fibrinogen & eGFR was -0.25 & -0.2 in DM & DN groups respectively. Thus eGFR was negatively correlated with fibrinogen. Urine A/C ratio had positive correlation with fibrinogen with a r value of 0.33 & 0.48 in DM & DN groups respectively.

Source of Funding

No financial support was received for the work within this manuscript.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

1 

C. E. Mogensen Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset DiabetesN Engl J Med198431063566010.1056/nejm198402093100605

2 

J B Meigs MA Mittleman DM Nathan GH Tofler DE Singer PM Murphy-Sheehy Hyperinsulinemia, Hyperglycemia, and Impaired HemostasisJAMA20002832221810.1001/jama.283.2.221

3 

B. B. Duncan M. I. Schmidt S. Offenbacher K. K. Wu P. J. Savage G. Heiss Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) StudyDiabetes Care1999227677210.2337/diacare.22.5.767

4 

I Juhan-Vague MC Alessi P Vague Thrombogenic and Fibrinolytic Factors and Cardiovascular Risk in Non-insulin-dependent Diabetes MellitusAnn Med19962843718010.3109/07853899608999095

5 

S. E. Kahn B. Zinman S. M. Haffner M. C. O'Neill B. G. Kravitz D. Yu Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 DiabetesDiabetes200655823576410.2337/db06-0116

6 

MM Suchitra MK Sheshu AR Bitla MA Rao S Alok Atherogenic dyslipidemia in diabetic nephropathy: lipoprotein (a), lipid ratios and atherogenic indexInt J Res Med Sci201314455910.5455/2320-6012.ijrms20131129

7 

A Festa R D'agostino G Howard L Mykkänen R P Tracy SM Haffner Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis StudyKidney Int200058417031010.1046/j.1523-1755.2000.00331.x

8 

G Venkataramana P Indira DVM Rao Changes of Plasma Total proteins, Albumin and Fibrinogen in Type 2 Diabetes mellitus- A Pilot studyIndian J Basic Appl Med Res20137267985

9 

CB Laurell Electrophoresis, Specific Protein Assays, or Both in Measurement of Plasma Proteins?Clin Chem19731919910210.1093/clinchem/19.1.99

10 

C A Alper Plasma Protein Measurements as a Diagnostic AidN Engl J Med197429162879010.1056/nejm197408082910606

11 

L M Killingsworth A report format for serum proteins.Clin Chem1978244728910.1093/clinchem/24.4.728

12 

O. P. Ganda C. F. Arkin Hyperfibrinogenemia: An important risk factor for vascular complications in diabetesDiabetes Care1992151012455010.2337/diacare.15.10.1245

13 

A Collier A Rumley A G Rumley Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuriaDiabetes19924190913

14 

A. Schmitz J. Ingerslev Haemostatic Measures in Type 2 Diabetic Patients with MicroalbuminuriaDiabetic Med199076521510.1111/j.1464-5491.1990.tb01435.x

15 

M Eraslan O Yenice H Kazokoglu D G Yavuz E Cerman H Celiker Increased serum sialic acid in diabetic retinopathy of type 1 diabetesGuoji Yanke Zazhi (Int Eye Sci)2013131019502



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 14-01-2021

Accepted : 19-02-2021


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/ 10.18231/j.ijn.2021.008


Article Metrics






Article Access statistics

Viewed: 1182

PDF Downloaded: 645